HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Lowers Price Target to $84
HC Wainwright & Co. analyst Oren Livnat maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $86 to $84.
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.
Pacira Reports FDA Approval Of Enhanced EXPAREL Manufacturing Process
-- New 200-liter suite doubles capacity to meet growing EXPAREL demand --
-- Patent covering enhanced manufacturing process extends proprietary position to January 2041 --
PARSIPPANY, N.J., Aug. 02, 2021 (GLOBE
JP Morgan Upgrades Pacira BioSciences to Overweight, Announces $75 Price Target
JP Morgan analyst Christopher Neyor upgrades Pacira BioSciences (NASDAQ:PCRX) from Neutral to Overweight and announces $75 price target.
Pacira BioSciences Reports EXPAREL Distribution Deal With Eurofarma In Latin America, No Terms Disclosed
Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it has entered into a distribution agreement with
Earnings Scheduled For May 4, 2021
Companies Reporting Before The Bell
• Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million.
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May.